Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep1032 | Pituitary - Clinical | ECE2017

Does cyproterone acetate therapy contribute to the observed elevation in serum prolactin levels in trans women?

Defreyne Justine , Nota Nienke , Perreira Cecilia , Thomas Schreiner , Daphne Fisher Alessandra , Guy T'Sjoen

Objective: Hormonal treatment in trans women (MtF transgender persons) in Europe usually consists of estrogens and anti-androgens, e.g. cyproterone acetate (CPA). After initiation of cross-sex hormone therapy, an elevation in serum prolactin levels is frequently observed in trans women, which was previously attributed to estrogen agents. This analysis evaluates whether CPA contributes to the elevation of prolactin in trans women receiving cross-sex hormones.<p class="abste...

ea0041gp146 | Paediatric Endocrinology &amp; Development | ECE2016

Breast development in male-to-female transgender patients after one year cross-sex hormonal treatment

de Blok Christel , Klaver Maartje , Nota Nienke , Dekker Marieke , den Heijer Martin

Background: In male to female transgender patients breast development is a key part in the process of feminization using cross sex hormone therapy. In the Endocrine Society’s clinical guideline ‘Endocrine treatment of transsexual persons’ the onset of breast growth is estimated as 3–6 months after starting cross sex hormone treatment. The maximum breast growth however is seen after 2–3 years. But how much growth, in centimeters or cup-sizes, we can exp...

ea0041ep961 | Steroid metabolism + action | ECE2016

Increase in insuline-like growh factor levels during cross-sex hormone treatment in transgender persons

Nota Nienke , Dekker Marieke , Klaver Maartje , Wiepjes Chantal , Heijboer Annemieke , den Heijer Martin

Background: Sex steroids probably stimulate growth-hormone secretion during puberty, which in turn contributes to the development of gender specific body characteristics. Hypothetically, adequate growth hormone levels in transgender persons are also important to achieve the best therapeutic results. The influence of cross-sex hormone treatment (CHT) at growth-hormone production in adult transgender persons is not yet elucidated.Objective: To investigate ...

ea0037ep130 | Steroids, development and paediatric endocrinology | ECE2015

Serum prolactin levels in transgender persons before and during cross-sex hormonal treatment

Nota Nienke , Klaver Maartje , den Heijer Martin , Dekker Marieke , Heijboer Annemieke

Introduction: Gender dysphoria refers to the incongruence between the subject’s experienced sex on the one hand and the assigned sex on the other hand. Several studies assume a relationship between oestrogen substitution therapy and serum prolactin levels.Aim: The aim of this study is to get more insight into the effect and time-course of changes in serum prolactin levels during cross-sex hormone therapy.Methods: This prospect...

ea0041ep958 | Steroid metabolism + action | ECE2016

Resting state functional connectivity is affected by testosterone treatment in female-to-male transgender persons

Nota Nienke , Burke Sarah , den Heijer Martin , Soleman Remi , Lambalk Cornelis , Veltman Dick , Cohen-Kettenis Peggy , Kreukels Baudewijntje

Background: Several resting state networks have been described in literature. Today, it is still unclear whether these networks are stable or can be influenced by sex hormones. Transgender persons offer a unique opportunity to study these hormonal influences.Objective: To examine the effects of cross-sex hormone treatment in transgender persons on two resting state networks involved in cognition and emotion, the default mode network and executive network...

ea0056p981 | Steroid metabolism + action | ECE2018

Facial feminization/masculinization: the effect of hormone treatment in transpersons

Tebbens Marieke , Nota Nienke , Liberton Niels , Meijer Brigitte , Kreukels Baudewijntje , Forouzanfar Tim , Verdaasdonk Ruud , den Heijer Martin

Background: Facial feminization or masculinization is particularly important in transpersons, both for self-image and social interaction. Females tend to have a smaller, rounder face, with more prominent cheeks and males tend to have a larger, more square face with frontal bossing. It is unknown whether cross-sex hormones can change these features. However, transgenders themselves often report facial changes due to hormone treatment. Therefore we aim to objectify if hormone tr...

ea0056p982 | Steroid metabolism + action | ECE2018

Polycythemia in transmen – Prevalence, determinants and outcome in a large cohort

Dijk Dennis van , Wiepjes Chantal , Blok Christel de , Klaver Maartje , Nota Nienke , Tebbens Marieke , Heijer Martin den , Conemans Elfi

Introduction: Testosterone is known to have an effect on hematocrit levels, with polycythemia as an unwanted side effect. An increase in hematocrit levels is also seen in transmen after starting cross-sex hormonal treatment (CHT) with testosterone. The aim of this study is to investigate the effect of cross-sex hormonal treatment with testosterone on hematocrit levels in the context of the safety aspects of this treatment. The prevalence, determinants and outcome of secondary ...

ea0056gp222 | Reproduction | ECE2018

Change in visceral fat and its relation with change in lipids in trans persons during hormonal therapy: results from a multicenter prospective study

Klaver Maartje , Wiepjes Chantal , de Blok Christel , Nota Nienke , Defreyne Justine , Schneider Thomas , Fisher Alessandra , T'Sjoen Guy , den Heijer Martin , de Mutsert Renee

Introduction: Excess visceral adipose tissue (VAT) is strongly related to multiple cardiovascular risk factors such as dyslipidemia. Hormonal therapy (HT) in trans persons affects total body fat and body fat distribution, but the effect on VAT and its relation to changes in lipids is unknown. The aim of our study was to investigate the effect of one year HT on changes in VAT and its relation with changes in total cholesterol, HDL, LDL, and triglycerides after one year of HT.</...

ea0056p955 | Female Reproduction | ECE2018

Breast cancer in transgender persons receiving gender affirming hormone treatment: results of a nationwide cohort study

JM de Blok Christel , Wiepjes Chantal M. , Nota Nienke M. , Engelen Klaartje van , Adank Muriel A. , Dreijerink Koen M.A. , Barbe Ellis , Konings Inge R.H.M. , den Heijer Martin

Background: Transpersons can receive gender affirming hormone therapy (HT) to induce physical changes. Little is known about the effect of HT on breast cancer (BC) risk.Objectives: To study the prevalence and characteristics of BC in transpersons with HT and to compare this prevalence with the general Dutch male and female population.Methods: Adult transpersons who were seen after 1991 and started HT in the VUmc were included. This...